$56.23
0.260.46%
At Close: -
$56.23
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Halozyme Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Analyze the earnings history of Halozyme Therapeutics using advanced sorting and filters.
Get Alert | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
HALO | Halozyme Therapeutics | $0.74 | $0.78 | — | — | $221.04M | $208.90M | — | — | 08/06/2024 | Get Alert |
HALO | Halozyme Therapeutics | $0.47 | $0.69 | $0.79 | 14.49% | $162.14M | $199.78M | $195.88M | -1.95% | 05/07/2024 | Get Alert |
HALO | Halozyme Therapeutics | $0.48 | $0.83 | $0.82 | -1.20% | $181.50M | $233.19M | $230.04M | -1.35% | 02/20/2024 | Get Alert |
HALO | Halozyme Therapeutics | $0.74 | $0.73 | $0.75 | 2.74% | $208.98M | $222.63M | $216.03M | -2.96% | 11/06/2023 | Get Alert |
HALO | Halozyme Therapeutics | $0.53 | $0.63 | $0.74 | 17.46% | $152.37M | $199.32M | $221.04M | 10.90% | 08/08/2023 | Get Alert |
HALO | Halozyme Therapeutics | $0.47 | $0.48 | $0.47 | -2.08% | $117.28M | $175.51M | $162.14M | -7.62% | 05/09/2023 | Get Alert |
HALO | Halozyme Therapeutics | $0.42 | $0.47 | $0.48 | 2.13% | $102.00M | $192.05M | $181.50M | -5.50% | 02/21/2023 | Get Alert |
HALO | Halozyme Therapeutics | $0.55 | $0.51 | $0.74 | 45.10% | $115.83M | $191.10M | $208.98M | 9.35% | 11/08/2022 | Get Alert |
HALO | Halozyme Therapeutics | $0.66 | $0.50 | $0.53 | 6.00% | $136.46M | $138.78M | $152.37M | 9.79% | 08/09/2022 | Get Alert |
HALO | Halozyme Therapeutics | $0.37 | $0.49 | $0.47 | -4.08% | $89.02M | $128.25M | $117.28M | -8.55% | 05/10/2022 | Get Alert |
HALO | Halozyme Therapeutics | $0.50 | $0.41 | $0.42 | 2.44% | $121.70M | $100.32M | $102.00M | 1.68% | 02/22/2022 | Get Alert |
HALO | Halozyme Therapeutics | $0.31 | $0.42 | $0.55 | 30.95% | $65.32M | $101.94M | $115.83M | 13.63% | 11/02/2021 | Get Alert |
HALO | Halozyme Therapeutics | $0.19 | $0.40 | $0.66 | 65.00% | $55.22M | $103.16M | $136.46M | 32.28% | 08/09/2021 | Get Alert |
HALO | Halozyme Therapeutics | -$0.04 | $0.32 | $0.37 | 15.62% | $25.35M | $84.88M | $89.02M | 4.88% | 05/10/2021 | Get Alert |
HALO | Halozyme Therapeutics | -$0.24 | $0.53 | $0.50 | -5.66% | $53.66M | $120.16M | $121.70M | 1.28% | 02/23/2021 | Get Alert |
HALO | Halozyme Therapeutics | -$0.17 | $0.20 | $0.25 | 25.00% | $46.23M | $60.91M | $65.32M | 7.23% | 11/02/2020 | Get Alert |
HALO | Halozyme Therapeutics | -$0.10 | $0.25 | $0.19 | -24.00% | $39.15M | $66.68M | $55.22M | -17.19% | 08/10/2020 | Get Alert |
HALO | Halozyme Therapeutics | $0.01 | -$0.02 | -$0.04 | -100.00% | $56.95M | $42.96M | $25.35M | -40.98% | 05/11/2020 | Get Alert |
HALO | Halozyme Therapeutics | -$0.01 | -$0.15 | -$0.24 | -60.00% | $60.23M | $56.93M | $53.66M | -5.74% | 02/24/2020 | Get Alert |
HALO | Halozyme Therapeutics | -$0.19 | -$0.12 | -$0.17 | -41.67% | $25.56M | $54.81M | $46.23M | -15.65% | 11/12/2019 | Get Alert |
HALO | Halozyme Therapeutics | -$0.16 | -$0.14 | -$0.10 | 28.57% | $35.20M | $42.76M | $39.15M | -8.45% | 08/06/2019 | Get Alert |
Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
---|---|---|---|---|
Mar 2024 | 2024-05-07 | $0.79 | $0.69 | 14.5 % |
Dec 2023 | 2024-02-20 | $0.82 | $0.83 | -1.20 % |
Sep 2023 | 2023-11-06 | $0.75 | $0.73 | 2.74 % |
Jun 2023 | 2023-08-08 | $0.74 | $0.63 | 17.5 % |
Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
---|---|---|---|---|
Mar 2024 | 2024-05-07 | $195.88M | $199.78M | -1.95 % |
Dec 2023 | 2024-02-20 | $230.04M | $233.19M | -1.35 % |
Sep 2023 | 2023-11-06 | $216.03M | $222.63M | -2.96 % |
Jun 2023 | 2023-08-08 | $221.04M | $199.32M | 10.9 % |
Halozyme Therapeutics (HALO) is scheduled to report earnings on August 6, 2024. The last reported earnings were for reported on May 7, 2024 for Q1.
The Actual EPS was $0.79, which beat the estimate of $0.69.
The Actual Revenue was $195.9M, which missed the estimate of $199.8M.
Browse earnings estimates, EPS, and revenue on all stocks.